| ASE-TECHNOLOGY-HOLDING-CO-LTD |
ASE-TECHNOLOGY-HOLDING-CO-LTD |
90%
|
Company entered into a three-year subscription-based agreement with ASE Technology Holding Co., Ltd. (ASEH), a related party |
| INABATA-CO-LTD |
INABATA-CO-LTD |
85%
|
We work with third parties to support the commercialization of our products across different markets and applications. We maintain relationships with companies including Inabata & Co. Ltd. and its Ta… |
| KENMEC-MECHANICAL-ENGINEERING-CO-LTD |
KENMEC-MECHANICAL-ENGINEERING-CO-LTD |
85%
|
We work with third parties to support the commercialization of our products across different markets and applications. We maintain relationships with companies including Inabata & Co. Ltd. and its Ta… |
| SOLOMON-TECHNOLOGY-CORPORATION |
SOLOMON-TECHNOLOGY-CORPORATION |
85%
|
We work with third parties to support the commercialization of our products across different markets and applications. We maintain relationships with companies including Inabata & Co. Ltd. and its Ta… |
| TAIWAN-INABATA-SANGYO-CO |
TAIWAN-INABATA-SANGYO-CO |
85%
|
We work with third parties to support the commercialization of our products across different markets and applications. We maintain relationships with companies including Inabata & Co. Ltd. and its Ta… |
| TOPCO-SCIENTIFIC-CO-LTD |
TOPCO-SCIENTIFIC-CO-LTD |
85%
|
We work with third parties to support the commercialization of our products across different markets and applications. We maintain relationships with companies including Inabata & Co. Ltd. and its Ta… |
| TOPMED-INTERNATIONAL-BIOTECH-CO-LTD |
TOPMED-INTERNATIONAL-BIOTECH-CO-LTD |
85%
|
We work with third parties to support the commercialization of our products across different markets and applications. We maintain relationships with companies including Inabata & Co. Ltd. and its Ta… |
| TRUSVAL-TECHNOLOGY-CO-LTD |
TRUSVAL-TECHNOLOGY-CO-LTD |
85%
|
We work with third parties to support the commercialization of our products across different markets and applications. We maintain relationships with companies including Inabata & Co. Ltd. and its Ta… |
| ASX |
ASE Technology Holding Co., Ltd. |
72%
|
Reciprocal relationship from ASX graph: Reciprocal relationship from AIMD graph: KY, is under common control with the Company. F- 25 Subsidiary ScentAI Inc. (“ScentAI”) is a wholly owned subsidiary o… |
| ASX |
ASE Technology Holding Co., Ltd. |
72%
|
KY, is under common control with the Company. F- 25 Subsidiary ScentAI Inc. (“ScentAI”) is a wholly owned subsidiary of the Company. The Company issued 1,160,000 shares of its common stock in exchang… |
| AI-NOSE-CORPORATION |
AI-NOSE-CORPORATION |
62%
|
hey would be anti-dilutive: Schedule of Computations of Diluted Weighted Average Shares Outstanding 2025 2024 For the Year Ended December 31, 2025 2024 Option and RSUs to purchase common stock 1,466 … |
| ASE-TEST-INC |
ASE-TEST-INC |
62%
|
extensive patent litigation. Competitors may claim that the Company’s products infringe upon their intellectual property. Resolution of patent litigation or other intellectual property claims is typi… |
| CO-LTD |
CO-LTD |
62%
|
r clinical study in Taiwan. From time to time, we evaluate our development priorities based on available resources, partner engagement, and market conditions. Our current focus emphasizes scaling the… |
| MANAGEMENT-GROUP-LLC |
MANAGEMENT-GROUP-LLC |
62%
|
recognized. The Company invoices its customers at the beginning of the contractual period. Amounts anticipated to be recognized within one year of the balance sheet date are recorded on the consolida… |
| NISSHINBO-MICRO-DEVICES-INC |
NISSHINBO-MICRO-DEVICES-INC |
62%
|
detection and process monitoring. In August 2025, we signed a three-year subscription-based order, valued at $2.1 million, to deploy 1,400 AI Nose units across ASEH’s three manufacturing sites. We ar… |
| SUBSIDIARY-SCENTAI-INC |
SUBSIDIARY-SCENTAI-INC |
62%
|
KY, is under common control with the Company. F- 25 Subsidiary ScentAI Inc. (“ScentAI”) is a wholly owned subsidiary of the Company. The Company issued 1,160,000 shares of its common stock in exchang… |
| SWISS-PHARMACEUTICAL-CO-LTD |
SWISS-PHARMACEUTICAL-CO-LTD |
62%
|
r clinical study in Taiwan. From time to time, we evaluate our development priorities based on available resources, partner engagement, and market conditions. Our current focus emphasizes scaling the… |
| TAIWAN-CARBON-NANO-TECHNOLOGY-CORP |
TAIWAN-CARBON-NANO-TECHNOLOGY-CORP |
62%
|
r clinical study in Taiwan. From time to time, we evaluate our development priorities based on available resources, partner engagement, and market conditions. Our current focus emphasizes scaling the… |
| TAIWAN-CARBON-NANO-TECHNOLOGY-CORPORATION |
TAIWAN-CARBON-NANO-TECHNOLOGY-CORPORATION |
62%
|
hey would be anti-dilutive: Schedule of Computations of Diluted Weighted Average Shares Outstanding 2025 2024 For the Year Ended December 31, 2025 2024 Option and RSUs to purchase common stock 1,466 … |
| TAIWAN-INABATA-SANGYO-CO-TOPCO-SCIENTIFIC-CO-LTD |
TAIWAN-INABATA-SANGYO-CO-TOPCO-SCIENTIFIC-CO-LTD |
62%
|
r clinical study in Taiwan. From time to time, we evaluate our development priorities based on available resources, partner engagement, and market conditions. Our current focus emphasizes scaling the… |
| TRUSVAL-TECHNOLOGY-CO-LTD-SOLOMON-TECHNOLOGY-COR |
TRUSVAL-TECHNOLOGY-CO-LTD-SOLOMON-TECHNOLOGY-COR |
62%
|
r clinical study in Taiwan. From time to time, we evaluate our development priorities based on available resources, partner engagement, and market conditions. Our current focus emphasizes scaling the… |
